Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-025 CAR-T for Relapsed/Refractory NKG2DL+ Tumors
NCT04550663Phase 1Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in solid tumor, hepatocellular carcinoma (HCC), colorectal cancer (CRC) and 1 more, sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Maximum Tolerated Dose at 90 days and Adverse Events and Serious Adverse Events at 28 days. Status: unknown.
02
Drugs
belumosudil
03
Conditions
solid tumorhepatocellular carcinoma (HCC)colorectal cancer (CRC)glioma
Beyond the preview
Go deeper on NCT04550663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550663.